Jian Fang

发表

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Xing Wang, Shi Yan, Shaolei Li, 2015, Clinical lung cancer.

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

J Zhang, Xiaoling Chen, Jian Fang, 2021, Cancer Immunology, Immunotherapy.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non‐small cell lung cancer

Xing Wang, Shi Yan, Shaolei Li, 2014, Thoracic cancer.

培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的随机、对照、多中心临床研究

Baolan Li, Li Zhang, Jian-hua Chang, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].

Xiaoling Chen, Jian Fang, Jun Nie, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer

J Zhang, Xiaoling Chen, Shaolei Li, 2014, Thoracic cancer.

Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC

Xiaoling Chen, Jian Fang, Yang Wang, 2018, Asia-Pacific journal of clinical oncology.

Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma

Xiaoling Chen, Jian Fang, Yang Wang, 2018, Thoracic cancer.

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

J Zhang, Hanxiao Chen, Qingwei Ma, 2020, Cancer cell international.

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

Jianxing He, Y. Shu, Yiping Zhang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

W. Liu, X. Yan, S. Jiao, 2022, World journal of clinical cases.

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Ying Cheng, Yi-long Wu, B. Han, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Ping Wang, Ying Cheng, C. Chiu, 2020 .

Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.

Gong-yan Chen, Yun-peng Yang, Zhehai Wang, 2022, Lung cancer.